Loading…
Citizen Petition Fairness and Accuracy Act of 2006
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 4,105 other S bills in the 109th — cohort avg 35d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2006 · year_end · Pharmacy
S. 3175, Life-Saving Medicines Export Act of 2006. H.R. 6257, Access to Life-Saving Medicine Act. S. 4016, Access to Life-Saving Medicine Act. Matters relating to the Best Pharmaceuticals for Children Act reauthorization and Pediatric Research Equity Act reauthorization. Matters relating to the Prescription Drug User Fee Act reauthorization. S. 3695, A bill to amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs. H.R. 5993, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs. S. 3981, Citizen Petition Fairness and Accuracy Act of 2006. S. 2300, Lower PRICED Drugs Act. H.R. 6022, Lower PRICED Drugs Act. H.R. 5533, Biodefense and Pandemic Vaccine and Drug Development Act of 2006. S. 2564, Biodefense and Pandemic Vaccine and Drug Development Act of 2006, Sec. 5.
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $680,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
2006 · year_end · Pharmacy
S. 3981, the Citizen Petition Fairness and Accuracy Act Abbreviated New Drug Application No. 76-396 for calcitonin-salmon nasal spray Hatch-Waxman Amendments S. 3582, the Preserve Access to Affordable Generics Act S. 3695, HR. 5993, to prohibit Authorized Generics during 180 day exclusivity HR 6257 & S. 4016, the Access to Life Saving Medicines Act S. 2300 & HR 6022, the Lower Priced Drugs Act
Client expense: $102,200 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE